Prospective Observational Study to Assess the Effectiveness and Safety of Lanreotide Autogel in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Asia Region
Latest Information Update: 21 Jul 2023
At a glance
- Drugs Lanreotide (Primary)
- Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms AIM-NETs
- 18 Jul 2023 Planned primary completion date changed from 30 Jan 2023 to 30 Jan 2024.
- 13 Jan 2021 New trial record